Vardenafil Hydrochloride Tablet
Product Images NDC 0527-2800

13 FDA label images from Lannett Company, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Vardenafil Hydrochloride (NDC 0527-2800). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Vardenafil Figure 1)

Chemical Structure (Vardenafil Figure 1)
Chemical structure diagram of Vardenafil Hydrochloride depicting its molecular formula and hydrochloride and hydrate components (x HCl x 3H2O). The structure shows characteristic rings and functional groups typical of Vardenafil's molecular composition.*
FDA Label Image

Figure 1 (Vardenafil Figure 2)

Figure 1 (Vardenafil Figure 2)
A set of three line graphs depicting the mean maximal change in systolic blood pressure, diastolic blood pressure, and heart rate over different timings of Vardenafil treatment before NTG. The x-axis represents time intervals (24h, 8h, 4h, 1h), and the y-axis shows the mean maximal change for each parameter with error bars.*
FDA Label Image

Figure 2 (Vardenafil Figure 3)

Figure 2 (Vardenafil Figure 3)
A line graph showing mean change in mmHg over a 6-hour period comparing placebo and Vardenafil 5 mg under two conditions: simultaneous and 6-hour separation. The y-axis indicates mean change (mmHg) from -15 to 15, and the x-axis shows time in hours from 0 to 6. Four data sets are plotted with different markers representing placebo and Vardenafil 5 mg at each condition.*
FDA Label Image

Figure 3 (Vardenafil Figure 4)

Figure 3 (Vardenafil Figure 4)
A line graph depicting mean change in mmHg over time in hours for placebo and Vardenafil 5 mg under simultaneous and 6-hour separation dosing conditions. The x-axis shows time in hours from 0 to 6, and the y-axis shows mean change in mmHg ranging approximately from -15 to 15, comparing blood pressure effects over time among the four groups.*
FDA Label Image

Figure 4 (Vardenafil Figure 5)

Figure 4 (Vardenafil Figure 5)
A line graph showing mean change in mmHg over time (hours) for Vardenafil at 10 mg and 20 mg doses compared to placebo in two stages. The x-axis represents time in hours (0 to 6), and the y-axis represents mean change in mmHg (-10 to 5). Solid and dashed lines with different markers distinguish the treatment groups and stages.*
FDA Label Image

Figure 5 (Vardenafil Figure 6)

Figure 5 (Vardenafil Figure 6)
A line graph showing mean change in mmHg over 6 hours comparing Vardenafil 5 mg and 10 mg with placebo in two stages. The x-axis represents time in hours, and the y-axis shows mean blood pressure change. Lines indicate variations in pressure for Vardenafil doses and placebo groups across the time points.*
FDA Label Image

Figure 6 (Vardenafil Figure 7)

Figure 6 (Vardenafil Figure 7)
A line graph titled "TERAZOSIN" showing the mean change in mmHg on the y-axis and time in hours on the x-axis. The graph compares placebo, 10 mg vardenafil, and 20 mg vardenafil under two conditions: 6-hour separation and simultaneous administration, using different symbols and line styles for each group over a 6-hour period.*
FDA Label Image

Figure 7 (Vardenafil Figure 8)

Figure 7 (Vardenafil Figure 8)
A line graph titled 'TAMSULOSIN' showing mean change in blood pressure (mmHg) over time (hours) with six different treatment conditions: placebo with 6-hour separation and simultaneous administration, and vardenafil 10 mg and 20 mg each with 6-hour separation and simultaneous administration. The graph plots mean change values from 0 to 10 mmHg on the y-axis over a 6-hour period on the x-axis for each condition.*
FDA Label Image

Figure 8 (Vardenafil Figure 9)

Figure 8 (Vardenafil Figure 9)
A line graph showing plasma concentration (µg/L) of Vardenafil Hydrochloride over time (hours). The graph depicts a peak concentration occurring within the first 2 hours, followed by a gradual decline in plasma concentration over 24 hours, with error bars indicating variability at each time point.*
FDA Label Image

2.5 mg Bottle Label (2.5 mg Bottle Label)

2.5 mg Bottle Label (2.5 mg Bottle Label)
Label for Vardenafil Hydrochloride Tablets 2.5 mg by Lannett Company, Inc. The label indicates 30 tablets per container, oral route, prescription only. Manufactured by Rivopharm SA, Switzerland, and distributed by Lannett Company, Inc., Philadelphia, PA. Contains phenylalanine 0.7 mg per 2.5 mg tablet. Includes dosage instructions and storage recommendations.*
FDA Label Image

5 mg Bottle Label (5 mg Bottle Label)

5 mg Bottle Label (5 mg Bottle Label)
Label for Vardenafil Hydrochloride Tablets 5 mg, oral tablets in a 30-tablet count package. Manufactured by Rivopharm SA, Switzerland, and distributed by Lannett Company, Inc. Includes storage instructions, dosage note to take one tablet as needed, and a warning for phenylketonurics about phenylalanine content. The label features a barcode and regulatory information.*
FDA Label Image

10 mg Bottle Label (10 mg Bottle Label)

10 mg Bottle Label (10 mg Bottle Label)
Label for Vardenafil Hydrochloride Tablets 10 mg, oral tablet form by Lannett Company, Inc. The package contains 30 tablets. The label includes a barcode, manufacturer information (Rivopharm SA, Switzerland), and dosing instructions. Storage recommendations specify controlled room temperature and caution for phenylketonurics.*
FDA Label Image

20 mg Bottle Label (20 mg Bottle Label)

20 mg Bottle Label (20 mg Bottle Label)
Packaging label for Vardenafil Hydrochloride Tablets 20 mg by Lannett Company, Inc. The label includes dosage form as tablets, strength of 20 mg, and a package count of 30 tablets. Manufacturer information lists Rivopharm SA in Switzerland, with distribution by Lannett Company in Philadelphia, PA. The label also shows the NDC number 0527-2803-32 and includes prescription-only designation and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.